SCWorx Receives Nasdaq Hearings Panel Decision Granting the Company’s Request to Continue its Listing on the Nasdaq Stock Market, Subject to Compliance Conditions

SCWorx (WORX) has secured conditional reinstatement of its Nasdaq listing after trading suspension in April 2026 due to failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Hearings Panel's favorable decision represents a critical reprieve for the company's continued market access.

The company operates in healthcare data normalization and supply chain optimization, a segment benefiting from ongoing healthcare digitalization trends. The conditional nature of reinstatement creates near-term execution risk, as management must satisfy unspecified compliance conditions within what are typically defined timeframes by Nasdaq.

This outcome reflects moderate positive momentum for WORX, as delisting would have triggered forced liquidation by many institutional holders. However, the initial trading suspension and ongoing compliance uncertainty suggest underlying operational or financial stress that requires monitoring. The stock likely carries elevated volatility risk during the compliance period.

Sector implication: This decision has limited broad-market correlation but signals health in the healthcare IT infrastructure space. Successful compliance could validate management's turnaround efforts and restore institutional investor confidence, while failure would accelerate downside pressure on healthcare technology plays with weak fundamentals.